Update of ELITE-II, BEST, CHAMP, and IMPRESS clinical trials in heart failure

K Witte; S Thackray; T Banerjee; A L Clark; J G Cleland

doi:10.1016/s1388-9842(00)00053-2

Update of ELITE-II, BEST, CHAMP, and IMPRESS clinical trials in heart failure

Eur J Heart Fail. 2000 Mar;2(1):107-12. doi: 10.1016/s1388-9842(00)00053-2.

Authors

K Witte¹, S Thackray, T Banerjee, A L Clark, J G Cleland

Affiliation

¹ The University of Hull, Department of Cardiology, Academic Unit of Cardiology, Castle Hill Hospital, Kingston upon Hull, UK.

PMID: 10742710
DOI: 10.1016/s1388-9842(00)00053-2

Abstract

The ELITE-II, BEST and CHAMP Trials were reported for the first time at the American Heart Association in November 1999. These trials provide valuable new information to guide clinical practice in the management of heart failure and of myocardial infarction, although none mandate a major change from current clinical practice. The IMPRESS trial of the vasopeptidase inhibitor, omapatrilat, indicated a promising new treatment for the management of heart failure.

MeSH terms

Adrenergic beta-Antagonists / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Antihypertensive Agents / therapeutic use
Captopril / therapeutic use
Exercise Tolerance
Heart Failure / drug therapy*
Humans
Losartan / therapeutic use
Pyridines / therapeutic use
Randomized Controlled Trials as Topic
Thiazepines / therapeutic use

Substances

Adrenergic beta-Antagonists
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Pyridines
Thiazepines
omapatrilat
Captopril
Losartan